- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01966783
Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis
May 3, 2019 updated by: Dr. Falk Pharma GmbH
Randomized, Double-blind, Multicentre Study to Compare the Efficacy and Safety of Budesonide Versus Mesalazine Suppository Versus a Combination Therapy of Budesonide/Mesalazine Suppositories in Patients With Acute Ulcerative Proctitis
The purpose of this study is to investigate the efficacy and safety of budesonide suppository for the treatment of acute ulcerative proctitis.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Anticipated)
320
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 12203
- Charité-Campus Benjamin Franklin Universitätsmedizin Berlin
-
Cologne, Germany, 51103
- Evang. Krankenhaus Kalk, Medical department
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Active ulcerative proctitis
- Diagnosis confirmed by endoscopy
- Established disease or new diagnosis
Exclusion Criteria:
- Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis, diverticular assoc. colitis, microscopic colitis
- Presence of proctitis of a different origin
- Prior bowel resection
- Presence of symptomatic organic disease of the gastrointestinal tract
- Asthma, tuberculosis, cardiovascular disease, diabetes mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract, infection if careful medical monitoring is not ensured
- Local intestinal infection
- Abnormal hepatic or renal function
- Oral/rectal/intravenous corticosteroids therapy
- Existing or intended pregnancy or breast-feeding
- Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Budesonide dosage 1
Budesonide 2 mg suppository
|
per day
|
Experimental: Budesonide dosage 2
Budesonide 4 mg suppository
|
per day
|
Active Comparator: Mesalazine
Mesalazine 1g suppository
|
per day
|
Experimental: Combination
Budesonide 2 mg suppository/Mesalazine 1 g suppository
|
per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Resolution of clinical symptoms
Time Frame: 8 weeks
|
Symptoms as reported in the diary
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of clinical and endoscopic remission
Time Frame: 8 weeks
|
Symptoms as reported in the diary, ulcerative colitis-disease activity index
|
8 weeks
|
Rate of improvement
Time Frame: 8 weeks
|
Symptoms as reported in the diary, ulcerative colitis-disease activity index
|
8 weeks
|
Rate of patients with clinical remission
Time Frame: 8 weeks
|
Symptoms as reported in the diary, ulcerative colitis-disease activity index
|
8 weeks
|
Rate of patients with endoscopic remission
Time Frame: 8 weeks
|
Ulcerative colitis-disease activity index
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Wolfgang Kruis, Professor, Evang. Krankenhaus Kalk, Medical department
- Principal Investigator: Britta Siegmund, Professor, Charité-Campus Benjamin Franklin Universitätsmedizin Berlin
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2013
Primary Completion (Actual)
August 1, 2015
Study Completion (Actual)
August 1, 2015
Study Registration Dates
First Submitted
October 9, 2013
First Submitted That Met QC Criteria
October 21, 2013
First Posted (Estimate)
October 22, 2013
Study Record Updates
Last Update Posted (Actual)
May 7, 2019
Last Update Submitted That Met QC Criteria
May 3, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Intestinal Diseases
- Rectal Diseases
- Proctitis
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Budesonide
- Mesalamine
Other Study ID Numbers
- BUS-2/UCA
- 2012-003362-41 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Proctitis
-
Medical University InnsbruckServier Affaires MédicalesRecruitingProctitis RadiationAustria
-
CSA Medical, Inc.WithdrawnRadiation Proctitis | Radiation Induced Proctitis
-
West China HospitalRecruitingProbiotics | Gut Microbiota | Bifidobacterium | Radiation Proctitis | GlutamineChina
-
Barmherzige Brüder ViennaRecruiting
-
Forest LaboratoriesTerminatedProctitis, UlcerativeUnited States, Poland, Canada
-
Dr. Falk Pharma GmbHTerminatedRadiation ProctitisGermany
-
University College London HospitalsUnknownRadiation Enteritis | Radiation ProctitisUnited Kingdom
-
Maria Sklodowska-Curie National Research Institute...Medical Centre for Postgraduate EducationCompleted
-
Cristcot LLCCristcot HCA LLCRecruitingUlcerative ProctitisSouth Africa, United States, Denmark, Philippines, Spain, Germany, India, Italy, Poland, Romania
Clinical Trials on Budesonide 2 mg suppository
-
Benaroya Research InstituteVirginia Mason Hospital/Medical CenterCompleted
-
University of Sao Paulo General HospitalCompletedProgesterone Resistance | Polycystic Ovary
-
Aquilon Pharmaceuticals S.A.Completed
-
G & W Laboratories Inc.CompletedInternal HemorrhoidsUnited States
-
Nivagen Pharmaceuticals Inc.CompletedInternal HemorrhoidsUnited States, India
-
Vectura LimitedCompleted
-
Cristcot LLCCristcot HCA LLCRecruitingUlcerative ProctitisSouth Africa, United States, Denmark, Philippines, Spain, Germany, India, Italy, Poland, Romania
-
Bausch Health Americas, Inc.Cosmo Technologies LtdCompletedUlcerative ColitisRussian Federation, United Kingdom, Latvia, Poland, Estonia, Belgium, Australia, Lithuania, France, Sweden, Israel, Italy, Romania, Slovakia, Ukraine
-
Vectura LimitedCompletedWheezing | Reactive Airway Disease | Mild AsthmaUnited States
-
University of WashingtonCompletedPancreatectomy; Hyperglycemia | Pancreatic Fistula | Pancreaticoduodenal; Fistula | Pancreatic LeakUnited States